Therapeutic oncology company RefleXion Medical has received U.S. Food and Drug Administration (FDA) clearance for a cutting-edge treatment for early and late-stage cancers.
Founded by Dr. Samuel Mazin (BASc ’02, computer engineering) in 2009, RefleXion’s mission is to advance innovative treatment in cancer care through a biology-guided radiotherapy (BgRT) it calls SCINTIX™.
SCINTIX is the only radiotherapy that allows each cancer’s unique biology to autonomously determine where and how much radiation to deliver, second by second, during actual treatment delivery.
Samuel Mazin, founder and CTO of RefleXion Medical.
The technology is a novel therapy for patients with tumours in the lung or bone arising from primary and metastatic cancer. It uses live, continuously updated data throughout the entire treatment session to determine delivery with greater precision.
“Autonomous radiotherapy was just a concept over a decade ago, but now for the first time in the history of cancer treatment, the individual biology of the cancer itself guides its own destruction,” Mazin, CTO at RefleXion, said in a media release.
Mazin was awarded the Faculty of Engineering 2021 Alumni Achievement Medal for Professional Achievement in recognition of his ground-breaking work to advance cancer treatment.